Pozitronový emisní tomograf má negativní prediktivní hodnoty pro progresi raného relapsu pro pacienty s reziduálním onemocněním po první řadě chemoterapie u pokročilých stádií Hodgkinova lymfomu

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F08%3A00001283" target="_blank" >RIV/00216208:11120/08:00001283 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Popis výsledku v původním jazyce

In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [F-18]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET- patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET- patients (95% confidence interval [CI], 94%-99%) and 86% for PET- patients (95% CI, 78%-95%, P = .011). The NPV forPET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET- patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remiss

Název v anglickém jazyce

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Popis výsledku anglicky

In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [F-18]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET- patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET- patients (95% confidence interval [CI], 94%-99%) and 86% for PET- patients (95% CI, 78%-95%, P = .011). The NPV forPET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET- patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remiss

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8033" target="_blank" >NR8033: Redukce toxicity primární léčby pokročilého Hodgkinova lymfomu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood

ISSN

0006-4971

e-ISSN

—

Svazek periodika

112

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

000260691300016

EID výsledku v databázi Scopus

—